Welcome to our dedicated page for Optimizerx SEC filings (Ticker: OPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for revenue drivers behind OptimizeRx鈥檚 digital health messaging platform or tracking when executives buy shares? This SEC filings hub surfaces the answers investors usually dig for in hundreds of pages. From growth in EHR integrations to pharma-sponsor concentration risk, every disclosure is here and searchable.
Use Stock Titan鈥檚 AI to move quickly:
- Instant summaries turn the OptimizeRx annual report 10-K simplified into an easy-to-scan brief that flags platform usage metrics and data-security risk factors.
- Redline comparisons highlight quarter-over-quarter changes inside the OptimizeRx quarterly earnings report 10-Q filing, letting you follow revenue trajectory without crunching spreadsheets.
- AG真人官方-time alerts stream OptimizeRx Form 4 insider transactions so you know about executive stock moves the moment they hit EDGAR.
Typical questions are answered as you browse: 鈥淗ow did OptimizeRx finance its last acquisition?鈥濃�攕ee the OptimizeRx 8-K material events explained. 鈥淲hat are management鈥檚 option grants?鈥濃�攐pen the OptimizeRx proxy statement executive compensation. Want to watch director trades? Check OptimizeRx insider trading Form 4 transactions and drill into each filing with AI commentary. Whether you need an OptimizeRx earnings report filing analysis before the call or prefer understanding OptimizeRx SEC documents with AI after hours, our platform covers every filing type with timely updates and plain-language insight.
OptimizeRx Corporation (OPRX) filed an 8-K on June 24, 2025 to disclose a governance change. Effective June 20, 2025, the Board of Directors expanded from five to six members and appointed CEO Stephen Silvestro to fill the new seat. Silvestro will serve until the 2026 annual meeting, subject to earlier resignation or removal. No other executive departures, financial data, or strategic transactions were reported. The company furnished a related press release as Exhibit 99.1; the information in Item 7.01 is deemed 鈥渇urnished,鈥� not 鈥渇iled,鈥� under the Exchange Act.
Aside from this board adjustment, the 8-K contains no updates on earnings, guidance, or operations. Therefore, the filing is primarily informational and unlikely to have a material impact on valuation or near-term cash flows.
FAQ
What is the current stock price of Optimizerx (OPRX)?
What is the market cap of Optimizerx (OPRX)?
What is the primary business function of OptimizeRx Corp?
How does OptimizeRx integrate with healthcare providers?
What technology does OptimizeRx use to enhance patient support?
How does the platform improve medication adherence?
What differentiates OptimizeRx in the digital health and pharma marketing space?
Who benefits from the services provided by OptimizeRx?
How does OptimizeRx ensure the security of patient information?
Can OptimizeRx's technology be used for various types of healthcare messaging?
